PureTech Health PLC PRTC's Karuna Files Public S1 for NASDAQ IPO
03 June 2019 - 4:01PM
RNS Non-Regulatory
TIDMPRTC
PureTech Health PLC
03 June 2019
3 June 2019
PureTech Health plc
PureTech Health Affiliate Karuna Files Public Registration
Statement for Proposed Initial Public Offering
PureTech Health plc (LSE: PRTC) announced that its affiliate,
Karuna Therapeutics, Inc. ("Karuna"), has filed a public
registration statement on Form S-1 with the U.S. Securities and
Exchange Commission (SEC) relating to a proposed initial public
offering of shares of its common stock. The number of shares to be
offered and the price range for the offering have not yet been
determined. The offering is subject to market conditions, and there
can be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
Karuna intends to list its common stock under the symbol "KRTX" on
The Nasdaq Global Market.
Goldman Sachs & Co. LLC and Citigroup are acting as joint
book-running managers for the proposed offering. Wells Fargo
Securities is also serving as a joint book-running manager. Wedbush
PacGrow is acting as co-manager.
A registration statement relating to these securities has been
filed with the SEC but has not yet become effective. These
securities may not be sold, nor may offers to buy be accepted,
prior to the time the registration statement becomes effective. The
offering will be made only by means of a prospectus. When
available, a copy of the preliminary prospectus may be obtained by
visiting the SEC's website at www.sec.gov or by contacting the
offices of Goldman Sachs & Co. LLC, Attention: Prospectus
Department, 200 West Street, New York, NY 10282, by telephone:
1-866-471-2526 or by emailing prospectus-ny@ny.email.gs.com;
Citigroup Global Markets Inc., Attention: Prospectus Department,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, or by phone at (800) 831-9146; or Wells Fargo
Securities, LLC, Attention: Equity Syndicate Department, 375 Park
Avenue, New York, NY 10152, or by telephone at 1-800-326-5897, or
by email at cmclientsupport@wellsfargo.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Karuna Therapeutics
Karuna is an innovative clinical-stage biopharmaceutical company
primarily focused on developing novel therapies to address
disabling neuropsychiatric conditions characterized by significant
unmet medical need. Karuna is currently conducting a Phase 2
clinical trial of its lead product candidate, KarXT
(Karuna-Xanomeline-Trospium), for the treatment of acute psychosis
in patients with schizophrenia and expects preliminary results in
late 2019. Karuna also plans to initiate clinical trials of KarXT
to evaluate its potential therapeutic benefit in other CNS
disorders, including psychosis in Alzheimer's disease, or AD, as
well as pain. Karuna, which was founded by PureTech Health (LSE:
PRTC), has a worldwide exclusive license for xanomeline and has a
patent portfolio more broadly covering selective muscarinic
targeting enabled by the KarXT approach.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRASSMFAEFUSELM
(END) Dow Jones Newswires
June 03, 2019 02:01 ET (06:01 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024